Transgene and BioInvent – first patient treated in Part B of Phase I trial
Category: Press release
Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024
2023 half year results and business update
Transgene Announces Upcoming Investor Meetings
Transgene Announces Upcoming Investor Meetings
Transgene receives $15.3 Million from the Sale of Securities Held for Sale
Transgene receives $15.3 million from the sale of securities held for sale
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
Transgene and NEC present New Data on TG4050 at ASCO 2023
Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023
Transgene immunological data demonstrating that TG4001 can induce T-cell responses
Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001
Transgene provides business update and Q1 2023 financial position
business update and Q1 2023 financial position 15
Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
First patient dosed in Phase I trial evaluating TG6050 15
